Drug Trial Radar · NCT04304053
Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention
Last checked: Nov 20, 2026Latest source record: Jun 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,300
Actual
Start
Mar 18, 2020
Primary completion
Jun 15, 2020
Study completion Jun 15, 2020
Sponsor
- Lead sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Germans Trias i Pujol Hospital; Department of Health, Generalitat de Catalunya; Laboratorios Gebro Pharma SA; Laboratorios Rubió; Institut Catala de Salut
- First posted
- Mar 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a research project to evaluate the efficacy of hydroxychloroquine for post-exposure prophylaxis and early treatment of Covid-19. The intervention entails administering prophylactic hydroxychloroquine to all contacts (Study 1) and treating non severe confirmed cases with hydroxychloroquine (Study 2).
Conditions
- COVID-19
Interventions
Treatment and prophylaxisDrug
Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7 Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.
Standard Public Health measuresOther
Isolation of patient and contact tracing as per national guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Study 1- Clinical and virological outcome in exposed contactsTime frame: Up to 14 days after start of treatment
- Study 1- Transmission of SARS-CoV-2 in exposed contactsTime frame: Up to 14 days after start of treatment
- Study 2- Virological outcome in index casesTime frame: Up to 7 days after start of treatment
- Study 2- Clinical outcome in index casesTime frame: Up to 28 days after start of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Departament de Salut
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.